Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9719810 | 0.82 | RAB9A (0.65) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL359708 | 0.80 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ANPC1LMNAPARP10 | |
| SCHEMBL741038 | 0.79 | PARP10 (0.56) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL1032275 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2RAB9ANPC1LMNATDP1 | |
| SCHEMBL18997786 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL13564630 | 0.78 | NPC1 (0.68) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL7189404 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL8228259 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL1903216 | 0.76 | GRM5 (0.45) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL12851363 | 0.76 | HRH3 (0.56) | SMN1; SMN2LMNATDP1HPGDHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138342-B2 | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds | High Point Pharmacueticals, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| EP-1787982-B1 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7700583-B2 | Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090325932-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090105289-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-1878721-A1 | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | NOVO NORDISK A/S (DK) | 2008-01-16 | — | — | EP | disclosed |
| EP-1787982-A2 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | Novo Nordisk A/S (DK) | 2007-05-23 | — | — | EP | disclosed |
| US-20060089349-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active compounds | NOVO NORDISK A/S (DK) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD17B1 | SMN1; SMN2 2477/4885RAB9A 2127/4885NPC1 343/4885 |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HSD11B1, HSD3B1, CES1 | SMN1; SMN2 3206/4885RAB9A 2534/4885NPC1 531/4885 |
| US-20090105289-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds | HSD11B1, HSD3B1, HSD17B1 | SMN1; SMN2 2622/4885RAB9A 2052/4885NPC1 383/4885 |
| US-20090325932-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HSD11B1, HSD3B1, HSD17B1 | SMN1; SMN2 3766/4885RAB9A 3950/4885NPC1 945/4885 |
| US-20060089349-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active compounds | HSD11B1, HSD3B1, HSD17B1 | SMN1; SMN2 2477/4885RAB9A 2127/4885NPC1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.